ESC 365 - Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding

ESC Premium Access

Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding

Session: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

Topic: Atrial fibrillation (AF)

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor Anders Nissen Bonde

Gentofte University Hospital, Gentofte (Denmark)

0 follower

4 more presentations in this session

State of the art in bleeding risk in atrial fibrillation.

Speaker: Professor I. Van Gelder (Groningen, NL)

Bleeding risk for non-valvular AF patients prescribed warfarin, or standard doses of apixaban 5mg BID, dabigatran 150mg BID or rivaroxaban 20mg QD in real-world practice: Findings from EHR

Speaker: Doctor G. Lip (Liverpool, GB)

Major bleeding among patients with atrial fibrillation treated with rivaroxaban or warfarin in Sweden. Interim results from an on-going post-authorization study

Speaker: Associate Professor L. Friberg (Stockholm, SE)

Future direction for research in antithrombotic therapy in atrial fibrillation.

Speaker: Professor E. Hylek (Boston, US)

Access the full session

Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?

Speakers: Doctor A. Nissen Bonde, Professor I. Van Gelder, Doctor G. Lip, Associate Professor L. Friberg, Professor E. Hylek

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources